 |
Cyclacel Pharmaceuticals to announce release of second quarter 2011 financial results
Aug 9, 2011
|
12.6 KB |
|
| |
Berkeley Heights, NJ, August 9, 2011 – Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the
Company), a biopharmaceutical company developing oral therapies
that target the various phases of cell cycle control for the
treatment of cancer and other serious disorders, will announce
second quarter ...
|
|
Cyclacel Pharmaceuticals amends its sapacitabine license agreement with Daiichi-Sankyo
Jul 18, 2011
|
12.6 KB |
|
| |
Berkeley Heights, NJ, July 18, 2011 – Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the
Company), today announced that effective July 11, 2011, Cyclacel
Limited, a wholly-owned subsidiary of the Company, entered into an
amendment of its license agreement, dated September 10, 2003
between Cyc...
|
|
Cyclacel announces closing of underwritten offering of common stock and warrants
Jul 7, 2011
|
13.6 KB |
|
| |
Berkeley Heights, NJ,
July 7, 2011 – Cyclacel Pharmaceuticals, Inc.
(NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the
Company), today announced that it has closed its previously
announced underwritten offering of an ag...
|
|
Cyclacel Pharmaceuticals, Inc. announces pricing of underwritten offering of common stock and warrants
Jul 1, 2011
|
14.2 KB |
|
| |
Berkeley Heights, NJ,
July 1, 2011 – Cyclacel Pharmaceuticals, Inc.
(NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), today
announced that it has priced an underwritten offering of an
aggregate 7,617,646 units at an offering price of $1.36 per unit
for gross proceeds of $10.36 m...
|
|
Interim results from Cyclacel clinical study highlight safety and efficacy of sequential administration of sapacitabine and decitabine in elderly patients with AML
Jun 6, 2011
|
17.5 KB |
|
| |
Berkeley Heights, NJ,
June 6, 2011 – Cyclacel Pharmaceuticals, Inc. NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the
Company), announced interim
results from an ongoing, multicenter, Phase 1/2 clinical trial
examining the safety and effectiveness of oral sapacitabine, the
Company's lead product candidate, administered sequentially ...
|
|
Cyclacel to report new sapacitabine clinical data at the American Society of Clinical Oncology Annual Meeting
May 19, 2011
|
14.9 KB |
|
| |
Berkeley Heights, NJ, May 19,
2011 – Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the
Company), announced today that new
interim data from an ongoing, multicenter, Phase 1/2 clinical trial
of oral sapacitabine, the Company's lead product c...
|
|
Cyclacel Pharmaceuticals reports financial results for first quarter 2011
May 12, 2011
|
18.1 KB |
|
| |
Berkeley Heights, NJ, May 12, 2011 –
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel or the Company), a biopharmaceutical company developing
oral therapies that target the various phases of cell cycle control
for the treatment of cancer and other serious disorders, today
reported its financial re...
|
|
Cyclacel to announce release of first quarter 2011 financial results
May 9, 2011
|
12.7 KB |
|
| |
Berkeley Heights, NJ, May 9,
2011 – Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel
or the Company), a biopharmaceutical company developing oral
therapies that target the various phases of cell cycle control for
the treatment of cancer and other serious disorders,
...
|
|
Cyclacel announces presentation of preclinical data demonstrating combination potential of clinical agents at AACR Annual Meeting
Apr 4, 2011
|
15.4 KB |
|
| |
Berkeley Heights, NJ, April 4, 2011 – Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the
Company), a biopharmaceutical company developing oral therapies
that target the various phases of cell cycle control for the
treatment of cancer and other serious disorders, today announced
the presentation of pr...
|
|
Cyclacel to participate in a lymphoma and leukemia panel at Leerink Swann cancer roundtable conference
Apr 4, 2011
|
12.2 KB |
|
| |
Berkeley Heights, NJ, April 4, 2011 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that Spiro Rombotis, Presiden...
|
|
Cyclacel Pharmaceuticals to restate 2009 Annual and 2010 Quarterly Financial Statements to correct Consolidated Balance Sheets and Consolidated Statement of Stockholders’ Equity; No impact on results of operations.
Mar 31, 2011
|
13.8 KB |
|
| |
Berkeley Heights, NJ, March 31, 2011 – Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the
Company), announced today that the Company's consolidated financial
statements as of and for the year ended December 31, 2009 and
quarterly consolidated financials statements for each of the three
months...
|
|
Cyclacel announces abstracts selected for presentation at American Association for Cancer Research Annual Meeting
Mar 29, 2011
|
14.9 KB |
|
| |
Berkeley Heights, NJ,
March 29, 2011 – Cyclacel Pharmaceuticals, Inc.
(NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the
Company), announced today that two
abstracts highlighting preclinical data for Cyclacel’s cell
cycle inhibi...
|
|
Cyclacel Pharmaceuticals reports fourth quarter and full year 2010 financial results
Mar 23, 2011
|
24.9 KB |
|
| |
Berkeley Heights, NJ, March 23, 2011 –
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel or the Company), announced today its financial results for
the fourth quarter and year ended December 31, 2010. Cyclacel also
provided an overview of its recent achievements and planned 2011
milestones.
...
|
|
Cyclacel to announce year end & fourth quarter 2010 financial results and presentation at upcoming conference
Mar 7, 2011
|
13.9 KB |
|
| |
Berkeley Heights, NJ,
March 7, 2011 – Cyclacel Pharmaceuticals, Inc.
(NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the
“Company”) today announced upcoming corporate
events.
...
|
|
Data Published in the Proceedings of the National Academy of Sciences highlight
Feb 17, 2011
|
18.6 KB |
|
| |
Berkeley Heights, NJ, February 17, 2011 –
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel or the Company), today announced the publication of
preclinical data in the Proceedings of the National Academy of
Sciences (PNAS), demonstrating that cyclin E plays a major role in
making Human Epidermal gr...
|
|
Cyclacel Pharmaceuticals to present at the 13th Annual BIO CEO & Investor Conference
Feb 1, 2011
|
14.5 KB |
|
| |
Berkeley Heights, NJ, February 1, 2011
–Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
“Cyclacel” or the “Company”) today
announced that the Company will present at the 13th
Annual BIO CEO & Investor Conference, being held at the Waldorf
Astoria Hotel in New York Ci...
|
|
Cyclacel begins pivotal Phase 3 “SEAMLESS” trial of sapacitabine as front-line treatment for AML under a SPA
Jan 11, 2011
|
18.6 KB |
|
| |
Berkeley Heights, NJ, January 11, 2011 -
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
“Cyclacel” or the “Company”), today
announced that it has opened enrollment of the SEAMLESS pivotal
Phase 3 trial for the Company’s sapacitabine oral capsules as
a front-line treatment of elder...
|
|
Cyclacel reviews 2010 achievements and key clinical development objectives for 2011
Jan 6, 2011
|
18.3 KB |
|
| |
Berkeley Heights, NJ, January 6, 2011 -
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
"Cyclacel" or the "Company") today reviewed 2010 achievements and
outlined the Company’s key clinical development objectives
for 2011, which will be highlighted at the Company’s
presentation during the 4th Annual...
|
|
Cyclacel announces topline results from APPRAISE Phase 2b study of seliciclib
Dec 21, 2010
|
19.1 KB |
|
| |
Berkeley Heights, NJ, December 21, 2010 –
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
“Cyclacel” or the “Company”), a
biopharmaceutical company developing oral therapies that target the
various phases of cell cycle control for the treatment of cancer
and other serious diseases,...
|
|
Cyclacel’s second-generation cyclin-dependent kinase inhibitor CYC065 demonstrates activity in multiple myeloma
Dec 5, 2010
|
17.8 KB |
|
| |
Berkeley Heights, NJ, December 5, 2010 –
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
“Cyclacel” or the “Company”), a
biopharmaceutical company developing oral therapies that target the
various phases of cell cycle control for the treatment of cancer
and other serious diseases, ...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter